Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

on. Patients who achieved a partial response, or had stable disease lasting through Week 52, were eligible for re-treatment, a booster, using the same protocol and dose as the initial treatment. Endpoints included safety, immunologic activity and antitumor activity.

Study Results

Treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fever and chills that were usually of low grade and typically lasted for one to two days following infusion. No patient discontinued the trial because of toxicity.

Treatment with NEUVENGE stimulated significant immune responses, which were shown to be enhanced following booster infusions. Twenty-two percent of patients had evidence of anti-cancer activity. This included one patient who experienced a partial response lasting approximately 6 months and three patients who had stable disease for over a year (74.9-94.0 weeks) without the addition of any other cancer therapy other than the continuation of bisphonates. Two additional patients had stable disease for up to 20 weeks. The study concluded that NEUVENGE was feasible, well-tolerated and showed evidence of anti-cancer activity.

"We are pleased that the results from this Phase I study of NEUVENGE demonstrate its potential as a treatment for advanced breast cancer patients," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "These data, together with the data we have published on the use of Provenge(R) (sipuleucel-T) in prostate cancer, further substantiate the promise of active cellular immunotherapies as new treatments for different types of cancer."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Mass. , June 2, 2015  PROMETRIKA, ... expanded its offerings with the addition of pharmacovigilance ... a world leader in safety data collection and ... and regulatory affairs professionals, and expert physicians, each ... provide clinical interpretation and monitoring of safety trends. ...
(Date:6/2/2015)... Today AmerisourceBergen, a global healthcare solutions leader, ... Olive Branch, MS ; ... . The facilities will operate within AmerisourceBergen,s existing ... increase supply chain efficiency and enhance patient care. ... ongoing investments, more than $1 billion over the last ...
(Date:6/2/2015)... 2015  Ashion™ Advanced Individual Medicine™ (AIM), ... medicine industry, announced today the launch of ... Precision Medicine Platform. AIM develops and manages ... regional healthcare systems, providing these centers with ... and operational support. AIM will use Syapse,s ...
Breaking Medicine Technology:PROMETRIKA Announces the Availability of Pharmacovigilance Services 2AmerisourceBergen to Build Three New Distribution Centers 2Ashion Advanced Individual Medicine Chooses Syapse to Enable Genomics-Based Cancer Care in the Community 2Ashion Advanced Individual Medicine Chooses Syapse to Enable Genomics-Based Cancer Care in the Community 3
... 17 deCODE genetics, Inc. (Nasdaq: DCGN ) today ... under Chapter 11 of the United States Bankruptcy Code with ... to facilitate the sale of substantially all of its assets. ... properties as a debtor-in-possession pursuant to Sections 1107 and 1108 ...
... , FREMONT, Calif., Nov. 16 Vermillion, Inc. (Pink ... will be presenting at the Lazard Capital Markets Sixth Annual ... scheduled for Tuesday, November 17, 2009 at 5:10 p.m. Eastern ... OVA1 Test is a qualitative serum test that combines the ...
Cached Medicine Technology:deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 2deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 3deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets 4
(Date:6/2/2015)... Milton Hershey School® graduate Vincent Klomps ’10 ... of the Physician Assistant Program’s entering class of 2015 ... with a white coat, which symbolizes his entrance into ... of Vincent’s accomplishments both at MHS and postgraduation,” said ... of how a top-notch education can lead to achievement ...
(Date:6/2/2015)... Warwick, RI (PRWEB) June 02, 2015 ... medical equipment distributor, has announced the acquisition of ... medical equipment distributor, effective May 29th, 2015. , With ... February 2015, this latest acquisition joins three premier organizations ... equipment to hospitals and healthcare facilities. By combining forces, ...
(Date:6/2/2015)... With a dedicated focus to become an employer of ... hired Leslie Young as director of human resources operations. Young ... understand and respond to the distinct needs of its employees ... states across the country. , “As we intensify our focus ... residents, we are making it an equal priority to provide ...
(Date:6/2/2015)... TU-Automotive Detroit is the biggest dedicated B2B connected car ... execs from GM, Chrysler, Mercedes, Ford, TomTom, Zipcar, Nissan ... update on the automotive technology industry and a look ... secure one of the remaining passes. , Justin Parker, ... are 70 sessions looking across the connected car space ...
(Date:6/2/2015)... June 02, 2015 Relias ... compliance solutions for the healthcare market, is partnering ... to offer 10 complimentary courses relating to mental ... safety professionals with additional resources to better understand ... are often the first responders to situations involving ...
Breaking Medicine News(10 mins):Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 3Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 4Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 2Health News:Relias Learning Partners with Behavioral Health and Developmental Disabilities Leaders to Offer Complimentary Resources to Public Safety Professionals 3
... white youth have the highest rate of diabetes of all ... 1 being the predominant kind of diabetes among youth. ... Colorado Health Sciences Center, Denver, presented the findings of the ... ,Estimates of the incidence of type 1 diabetes mellitus ...
... cancer treatment will develop one or more chronic health problems ... its treatment, a study released Tuesday suggested. ... 1,300 childhood cancer survivors found that 75 percent went on ... time they reached their mid 20s, or early 30s at ...
... are at an increased risk of jaw or facial ... cancer-related bone lesions, elevated levels of calcium in ... recent studies have found an association between the use ... facial bones, a condition in which poor blood supply ...
... set to turn into a "no-smoking zone" by mid-July this year. ... be fully enforced from July 15 and will cover markets, restaurants ... users annually in the country. , ,The establishment says ... utilities will be allowed to set up a separate area for ...
... 27 (IANS) Nearly 100 people have been bitten and injured ... no anti-rabies vaccines in the government hospitals to treat the ... jackal has attacked and injured villagers - including women and ... block of the district, about 200 km from here. ...
... found that weight management program cuts diabetes risk and ... mass index (BMI) in overweight children. ... Yale School of Medicine was more successful at plummeting ... clinic-based weight counselling. ,Mary Savoye-Desanti, research associate ...
Cached Medicine News:Health News:Whites Have Highest Risk of Diabetes in U.S 2Health News:Childhood Cancer can Lead to Chronic Health Problems Later in Life: Study 2Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:Chandigarh Set to Be No-smoking Zone from July 15 2Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
Medicine Products: